FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021982069> ?p ?o ?g. }

• W2021982069 endingPage "422" @default.
• W2021982069 startingPage "420" @default.
• W2021982069 abstract "T OPICALOCULARCHLORAMPHENICOL EYEDROPSARE relatively inexpensive and have broad-spectrum coverage of most gram-positive, gram-negative, and anaerobic bacteria. Worldwide, it is estimated that more than 50% of the world use topical chloramphenicol as a first-line agent in the treatment of conjunctivitis. The topical eye drop form of chloramphenicol became available in 1948 and the first fatality from eye drops was reported in 1955. In 1982, Fraunfelder reported another fatality associated with this medication. A subsequent research letter in 1993 reviewed all known case reports of this adverse drug reaction, with 23 blood dyscrasias leading to 12 deaths. In 2007, chloramphenicol eye drops’ relation to aplastic anemia and blood dyscrasias was classified as ‘‘probable’’ according to World Health Organization (WHO) criteria, based on the known published case reports and the spontaneous reports submitted to the National Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute, Portland, Oregon, USA; www. eyedrugregistry.com). Within 2 years of the 1982 case report of death associated with topical ocular chloramphenicol, sales in the United States declined by 90% and the Physicians Desk Reference placed a black box warning that read: ‘‘.ocular chloramphenicol should not be used unless there is no alternative.’’ However, most countries continued to use the eye drop form of chloramphenicol, and in 2002 England made it the first-line drug of choice for conjunctivitis and it was made available over the counter without the need for a prescription. The rarity of this adverse drug reaction makes it difficult to study with any certainty. Some patients are genetically predisposed to develop blood dyscrasias when they are prescribed chloramphenicol systemically, and it stands to reason that this would hold true for topical administration as well. Published studies from around the world estimate the incidence of idiopathic blood dyscrasia at around 1 in 2 000 000 and drug-related incidence as higher, depending on the medication. What is the incidence of blood dyscrasia or aplastic anemia from topical ocular chloramphenicol? This answer is not known; however, there is an estimation based on population studies published since" @default.
• W2021982069 created "2016-06-24" @default.
• W2021982069 creator A5045328356 @default.
• W2021982069 date "2013-09-01" @default.
• W2021982069 modified "2023-09-23" @default.
• W2021982069 title "Restricting Topical Ocular Chloramphenicol Eye Drop Use in the United States. Did We Overreact?" @default.
• W2021982069 cites W1959657781 @default.
• W2021982069 cites W1971396828 @default.
• W2021982069 cites W1981677100 @default.
• W2021982069 cites W2005831084 @default.
• W2021982069 cites W2007224501 @default.
• W2021982069 cites W2015302028 @default.
• W2021982069 cites W2039356467 @default.
• W2021982069 cites W2042680435 @default.
• W2021982069 cites W2071863453 @default.
• W2021982069 cites W2074062305 @default.
• W2021982069 cites W2095556292 @default.
• W2021982069 cites W2334371974 @default.
• W2021982069 doi "https://doi.org/10.1016/j.ajo.2013.05.004" @default.
• W2021982069 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23953152" @default.
• W2021982069 hasPublicationYear "2013" @default.
• W2021982069 type Work @default.
• W2021982069 sameAs 2021982069 @default.
• W2021982069 citedByCount "20" @default.
• W2021982069 countsByYear W20219820692014 @default.
• W2021982069 countsByYear W20219820692015 @default.
• W2021982069 countsByYear W20219820692016 @default.
• W2021982069 countsByYear W20219820692017 @default.
• W2021982069 countsByYear W20219820692018 @default.
• W2021982069 countsByYear W20219820692019 @default.
• W2021982069 countsByYear W20219820692020 @default.
• W2021982069 countsByYear W20219820692021 @default.
• W2021982069 countsByYear W20219820692023 @default.
• W2021982069 crossrefType "journal-article" @default.
• W2021982069 hasAuthorship W2021982069A5045328356 @default.
• W2021982069 hasConcept C118487528 @default.
• W2021982069 hasConcept C119767625 @default.
• W2021982069 hasConcept C16005928 @default.
• W2021982069 hasConcept C2777625524 @default.
• W2021982069 hasConcept C71924100 @default.
• W2021982069 hasConceptScore W2021982069C118487528 @default.
• W2021982069 hasConceptScore W2021982069C119767625 @default.
• W2021982069 hasConceptScore W2021982069C16005928 @default.
• W2021982069 hasConceptScore W2021982069C2777625524 @default.
• W2021982069 hasConceptScore W2021982069C71924100 @default.
• W2021982069 hasIssue "3" @default.
• W2021982069 hasLocation W20219820691 @default.
• W2021982069 hasLocation W20219820692 @default.
• W2021982069 hasOpenAccess W2021982069 @default.
• W2021982069 hasPrimaryLocation W20219820691 @default.
• W2021982069 hasRelatedWork W14214530 @default.
• W2021982069 hasRelatedWork W1569669064 @default.
• W2021982069 hasRelatedWork W1924698967 @default.
• W2021982069 hasRelatedWork W2128434532 @default.
• W2021982069 hasRelatedWork W2558799833 @default.
• W2021982069 hasRelatedWork W2738981461 @default.
• W2021982069 hasRelatedWork W3000507794 @default.
• W2021982069 hasRelatedWork W3111144589 @default.
• W2021982069 hasRelatedWork W4234833016 @default.
• W2021982069 hasRelatedWork W4297184974 @default.
• W2021982069 hasVolume "156" @default.
• W2021982069 isParatext "false" @default.
• W2021982069 isRetracted "false" @default.
• W2021982069 magId "2021982069" @default.
• W2021982069 workType "article" @default.